Skip to Main content Skip to Navigation
Master Thesis

Efficacité et tolérance de l'Urolift®, expérience préliminaire

Abstract : Background: Urolift® implants are a minimally invasive alternative to surgical treatment of benign prostatic hyperplasia. This treatment can be offered to preserve ejaculations or to accelerate post-operative recovery. The objective of this work was to evaluate the efficiency and safety of Urolift® treatment in our experience compared to previously published data. Materials and Methods: a retrospective analysis was conducted including all patients treated with Urolift® in our institution. The main outcome was the 3-month IPSS score. Secondary endpoints were the occurrence of complications and adverse events. Results: the analysis included 20 consecutive patients. The median age was 65,5 years, the prostatic volume 47mL and the IPSS score 24. The first 3 patients were operated on under general anesthesia and the following 12 under local anesthesia. All hospitalizations were outpatient, the median operating time was 10,5 minutes and no bladder catheter was placed postoperatively. Urinary burns were the main reported adverse event. Three acute urine retentions and 4 urinary tract infections occurred during the first month. The median recovery time, estimated retrospectively, was 10 days. At 3 months, the median IPSS score was 8,5, a decrease of 15,5 points (p=0.009). Three patients did not respond to Urolift® treatment and required HoLEP reprocessing within a median of 7 months. Conclusion: the analysis of this preliminary experiment confirmed that the improvement in the IPSS score after Urolift® was in compliance with previously published data, as was the absence of serious complications and a short recovery time
Complete list of metadatas

Cited literature [74 references]  Display  Hide  Download

https://dumas.ccsd.cnrs.fr/dumas-02433811
Contributor : Médecine Ub <>
Submitted on : Thursday, January 9, 2020 - 2:54:09 PM
Last modification on : Saturday, January 18, 2020 - 1:30:22 AM

File

Med_spe_2019_Dupitout.pdf
Files produced by the author(s)

Identifiers

  • HAL Id : dumas-02433811, version 1

Collections

Citation

Laure Dupitout. Efficacité et tolérance de l'Urolift®, expérience préliminaire. Sciences du Vivant [q-bio]. 2019. ⟨dumas-02433811⟩

Share

Metrics

Record views

27

Files downloads

1